tradingkey.logo
tradingkey.logo
Buscar

Vivos Therapeutics Inc

VVOS
Añadir a la lista de seguimiento
0.453USD
-0.045-9.05%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
4.21MCap. mercado
PérdidaP/E TTM

Más Datos de Vivos Therapeutics Inc Compañía

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

Información de Vivos Therapeutics Inc

Símbolo de cotizaciónVVOS
Nombre de la empresaVivos Therapeutics Inc
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoHuntsman (R. Kirk)
Número de empleados109
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 11
Dirección7921 Southpark Plaza,
CiudadLITTLETON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal80120
Teléfono18669084867
Sitio Webhttps://vivos.com/
Símbolo de cotizaciónVVOS
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoHuntsman (R. Kirk)

Ejecutivos de Vivos Therapeutics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Mr. Leonard J. (Lenny) Sokolow, CPA
Mr. Leonard J. (Lenny) Sokolow, CPA
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Mr. Leonard J. (Lenny) Sokolow, CPA
Mr. Leonard J. (Lenny) Sokolow, CPA
Independent Director
Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Vivos Therapeutics Inc?

Los cinco principales accionistas de Vivos Therapeutics Inc son: Mr. Bradford K. (Brad) Amman

¿Cuántas instituciones poseen acciones de Vivos Therapeutics Inc (VVOS)?

A fecha de 2026Q1, 50 instituciones poseen acciones de Vivos Therapeutics Inc, con un valor de mercado combinado de aproximadamente 1.10M, lo que representa el 8.12% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -71775.00.

¿Cuál es la mayor fuente de ganancias de Vivos Therapeutics Inc?

El 2026Q1, el segmento empresarial Sleep testing services generó la ganancia más alta para Vivos Therapeutics Inc, ascendiendo a 2.56M y representando el 37.74% de la ganancia total.